Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive‐Stage Small Cell Lung Cancer

BACKGROUND: Small cell lung cancer (SCLC) represents approximately 15% of lung cancers, and approximately 70% are diagnosed as extensive‐stage SCLC (ES‐SCLC). Although ES‐SCLC is highly responsive to chemotherapy, patients typically progress rapidly, and there is an urgent need for new therapies. Im...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Melosky, Barbara, Cheema, Parneet K., Brade, Anthony, McLeod, Deanna, Liu, Geoffrey, Price, Paul Wheatley, Jao, Kevin, Schellenberg, Devin D., Juergens, Rosalyn, Leighl, Natasha, Chu, Quincy
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648366/
https://ncbi.nlm.nih.gov/pubmed/32860288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0193
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados